期刊文献+

miR-126报告基因载体的构建及其功能鉴定

Construction of miR-126 Reporter Gene Vector and Detection of Its Function
原文传递
导出
摘要 目的:根据miR-126的预测靶点构建荧光素酶报告基因重组质粒,并进行功能鉴定。方法:利用sanger数据库提供的miR-126靶序列设计引物,PCR扩增目的微小RNA(microRNAs,miRNAs)靶基因3'非编码区(three-prime untranslated regions,3'UTRs)序列,PCR产物双酶切,后连入经过同样双酶切的pGL3-control载体中,连接产物转化大肠杆菌DH5α,进行阳性克隆鉴定。同样,将候选靶基因3'UTRs突变,突变型3'UTR克隆入pGL3-control报告载体,构建野生型和突变型的报告基因重组质粒。将野生型和突变型的报告基因载体分别和化学合成的microRNA以及内参质粒共转染293TN细胞,进行双荧光素酶检测。结果:成功构建miR-126报告基因野生型和突变型重组质粒pGL3-VEGF-A-3'UTR和pGL3-VEGF-A-3'UTR,质粒测序及酶切结果完全正确。瞬时转染实验显示,过表达miR-126能直接抑制VEGF-A-3'UTRs报告基因活性。结论:miR-126对VEGF-A具有靶向调节功能。 Objective: To construct miR-126 luciferase reporter gene vector according to miR-126 predicted target sequences and to detect its function. Methods: The primers were designed and amplified by using the putative target site for miR-126 predicted by Sanger database and inserted at the XbaI site, and immediately downstream of the luciferase gene in the pGL3-control vector. A mutant version with a deletion the site of perfect complementarity was also generated. Wild type and mutant recombinant plasmid for pGL3-vegfa -2-3'UTR and pGL3-mutvegfa -2-3'UTR were constructed and confirmed by sequencing. Twenty four hours before transfection, pGL3-vegfa-3'UTR or pGL3-mutvegfa-3'UTR plus pRL-TK were transfect alone or in combination with miR-126 mimics. Luciferase activity was measured 24hr after transfection. Results: pGL3-vegfa-3'UTR and pGL3-mut vegfa-3'UTR recombined luciferase reporter gene vector were constructed successfully, and the result of sequencing and double digesting of recombined plasrnid were completely correct. The experiment showed that luciferase activity of pGL3-vegfa-3'UTR reporter gene decreased after miR-126 overexpression. Conclusion: VEGF-A is the target ofmiR-126.
出处 《现代生物医学进展》 CAS 2014年第5期801-804,共4页 Progress in Modern Biomedicine
基金 国家自然科学基金青年科学基金项目(81100296) 上海市青年科技启明星计划项目(13QA1402500)
关键词 MIR-126 荧光素酶报告基因 靶基因 miR-126 Luciferase reporter gene Target gene
  • 相关文献

参考文献20

  • 1Okamura K. Diversity of animal small RNA pathways and their biolo- gical utility[J]. Wiley Interdiscip Rev RNA, 2012, 3(3): 351-368.
  • 2O'Connell RM, Ran DS, Baltimore D, et al. microRNA regulation of inflammatory responses[J[. Annu Rev Immunol, 2012, 30:295-312.
  • 3Chistiakov DA, Sobenin IA, Orekhov AN, et al. Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascul- ar pathology[J[. Drug Deliv, 2012, 19(8): 392-405.
  • 4Witkos TM, Koscianska E, Krzyzosiak WJ, et al. Practical Aspects of microRNA Target Prediction[J]. Curr Mol Med, 2011, 11(2): 93-109.
  • 5Meister J, Schmidt MHI miR-126 and miR-126*: new players in cancer[J[. Scientific World Journal, 2010, 10:2090-2100.
  • 6Li Z, Chen J. In vitro functional study ofmiR-126 in leukemia[J[. Me- thods Mol Biol, 2011,676:185-195.
  • 7Yan T, Liu Y, Cui K, et al. MiR-126 regulates EPCs ftmction: implica- tions for a role ofmiR-126 in preeclampsia[J]. J Cell Biochem, 2013.
  • 8Zhang Y, Yang P, Sun T, et al. miR- 126 and miR- 126(*) repress recru- itment of mesenchymal stem cells and inflammatory monocytes to inh- ibit breast cancer metastasis[J]. Nat Cell Biol, 2013, I5(3): 284-294.
  • 9Shi H, Chert L, Wang H, et al. Synergistic induction of miR-126 by hy- poxia and HDAC inhibitors in cardiac myocytes[J]. Biochem Biophys Res Commun, 2013, 430(2): 827-832.
  • 10Shen J, Stass SA, Jiang F, et al. MicroRNAs as potential biomarkers in human solid tumors[J]. Cancer Lett, 2013, 329(2): 125-236.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部